Walleye Capital LLC Vaxcyte, Inc. Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $5.04 Million - $6.83 Million	-84,214 Reduced 73.92%	29,707 $2.03 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $5.17 Million - $7.22 Million	113,921 New	113,921 $7.15 Million
Q2 2023 Aug 14, 2023	SELL	$34.66 - $54.07 $999,663 - $1.56 Million	-28,842 Reduced 32.82%	59,041 $2.95 Million
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $2.01 Million - $2.61 Million	-55,333 Reduced 38.64%	87,883 $3.29 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $1.73 Million - $4.03 Million	83,956 Added 141.67%	143,216 $6.87 Million
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $2.25 Million - $2.96 Million	-103,865 Reduced 63.67%	59,260 $1.42 Million
Q2 2022 Aug 08, 2022	BUY	$17.68 - $26.58 $1.66 Million - $2.49 Million	93,673 Added 134.87%	163,125 $3.55 Million
Q1 2022 May 16, 2022	BUY	$17.46 - $26.36 $1.21 Million - $1.83 Million	69,452 New	69,452 $1.68 Million

290

110M

248K

109K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $6.26B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.